AcelRx Pharma (ACRX) Misses Q4 EPS by 6c

AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.06), $0.06 worse than the analyst estimate of $0.00.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Target raises full-year sales forecast amid ongoing turnaround drive
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns